Clinical Trials in Pazardzhik, Bulgaria
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled143 locationsNCT06159673
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled482 locationsNCT05878769
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200